Sector News

Pfizer spinout Cerevel hires Coles as CEO

September 9, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Tony Coles has taken up the CEO role at Pfizer-spinout Cerevel Therapeutics. The appointment puts the man who led Onyx Pharmaceuticals to a $10 billion takeover in charge of using $350 million of Bain Capital’s money to advance a pipeline of neuroscience programs.

Cerevel spun out of Pfizer with three clinical-phase assets and the major Bain investment almost one year ago. Since then, Cerevel has put together an executive team, bringing long-term Merck staffer John Renger on board as chief scientific officer and hiring people from Sangamo Therapeutics and Bain to fill other C-suite posts.

Now, Cerevel has filled its top position. Coles began working with Cerevel as chair of its board late last year but remained focused on Yumanity Therapeutics, the biotech he co-founded and led until very recently.

Earlier this month, Richard Peters took over as CEO of Yumanity. Coles transitioned to the executive chairperson role upon the appointment of Peters, but the change nonetheless left him with capacity to take on more work. Cerevel is the beneficiary of the change.

The Pfizer spinout becomes the fourth company Coles has run. Coles got his first shot at being CEO at NPS Pharmaceuticals. After three years at NPS, Coles moved to Onyx, where his success in guiding Kyprolis to market attracted a buyout bid from Amgen. Coles set up Yumanity shortly after the sale of Onyx and ran it up to the start of this month.

At Cerevel, Coles inherits a fairly advanced R&D pipeline. Cerevel’s lead candidates are a dopamine D1/5PA agonist and a GABA A positive modulator, both of which are in phase 2. Those drugs are trailed by two phase 1 assets and a clutch of preclinical programs.

With a team in place and money to spend, Cerevel plans to start six clinical trials involving the drugs by the end of next year. If some of Cerevel’s bets come off, it has a shot at improving outcomes for patients with epilepsy, Parkinson’s disease, psychosis and addiction as well as fulfilling its ambition to grow into a leading neuroscience company.

By Nick Paul Taylor

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2019

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Life sciences

LinkedIn Twitter FacebookWhen Amgen said it would hand over $13.4 billion for Celgene’s hit psoriasis drug Otezla in August, analysts agreed it had overpaid by $2 billion. But they also […]

November 21, 2019

Sanofi CEO’s strategy blueprint may include consumer health spinoff or merger: Bloomberg

Life sciences

LinkedIn Twitter FacebookSanofi CEO Paul Hudson has been on the job for just over two months, and he’s prepping for a big strategy reveal next month. One thing that might […]

November 21, 2019

The Medicines Company surges on rumours of Novartis takeover

Life sciences

LinkedIn Twitter FacebookShares in The Medicines Company have leapt on rumours that Novartis is eyeing a takeover of the company and its promising new cardiovascular drug inclisiran. A report from […]

Subscribe to our Weekly Newsletter

We're easy to reach